These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 25736040)

  • 1. PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients.
    Oshiro C; Kagara N; Naoi Y; Shimoda M; Shimomura A; Maruyama N; Shimazu K; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2015 Apr; 150(2):299-307. PubMed ID: 25736040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.
    Nakauchi C; Kagara N; Shimazu K; Shimomura A; Naoi Y; Shimoda M; Kim SJ; Noguchi S
    Clin Breast Cancer; 2016 Oct; 16(5):418-423. PubMed ID: 27265061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of preoperative and postoperative circulating tumour DNA (ctDNA) with PIK3CA gene mutation with risk of recurrence in patients with non-metastatic breast cancer.
    Hassan F; Wang JH; O'Leary DP; Corrigan M; Redmond HP
    Surg Oncol; 2024 Jun; 54():102060. PubMed ID: 38603927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer.
    Dirican E; Kaya Z; Gullu G; Peker I; Ozmen T; Gulluoglu BM; Kaya H; Ozer A; Akkiprik M
    Asian Pac J Cancer Prev; 2014; 15(21):9327-33. PubMed ID: 25422220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA.
    Kim ST; Lira M; Deng S; Lee S; Park YS; Lim HY; Kang WK; Mao M; Heo JS; Kwon W; Jang KT; Lee J; Park JO
    Oncotarget; 2015 Nov; 6(37):40026-35. PubMed ID: 26498688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.
    Ramirez-Ardila DE; Helmijr JC; Look MP; Lurkin I; Ruigrok-Ritstier K; van Laere S; Dirix L; Sweep FC; Span PN; Linn SC; Foekens JA; Sleijfer S; Berns EM; Jansen MP
    Breast Cancer Res Treat; 2013 May; 139(1):39-49. PubMed ID: 23592373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR
    Moynahan ME; Chen D; He W; Sung P; Samoila A; You D; Bhatt T; Patel P; Ringeisen F; Hortobagyi GN; Baselga J; Chandarlapaty S
    Br J Cancer; 2017 Mar; 116(6):726-730. PubMed ID: 28183140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of cancer DNA in plasma of patients with early-stage breast cancer.
    Beaver JA; Jelovac D; Balukrishna S; Cochran R; Croessmann S; Zabransky DJ; Wong HY; Toro PV; Cidado J; Blair BG; Chu D; Burns T; Higgins MJ; Stearns V; Jacobs L; Habibi M; Lange J; Hurley PJ; Lauring J; VanDenBerg D; Kessler J; Jeter S; Samuels ML; Maar D; Cope L; Cimino-Mathews A; Argani P; Wolff AC; Park BH
    Clin Cancer Res; 2014 May; 20(10):2643-2650. PubMed ID: 24504125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging.
    García-Saenz JA; Ayllón P; Laig M; Acosta-Eyzaguirre D; García-Esquinas M; Montes M; Sanz J; Barquín M; Moreno F; Garcia-Barberan V; Díaz-Rubio E; Caldes T; Romero A
    BMC Cancer; 2017 Mar; 17(1):210. PubMed ID: 28330468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study.
    Tzanikou E; Markou A; Politaki E; Koutsopoulos A; Psyrri A; Mavroudis D; Georgoulias V; Lianidou E
    Mol Oncol; 2019 Dec; 13(12):2515-2530. PubMed ID: 31254443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.
    Pereira E; Camacho-Vanegas O; Anand S; Sebra R; Catalina Camacho S; Garnar-Wortzel L; Nair N; Moshier E; Wooten M; Uzilov A; Chen R; Prasad-Hayes M; Zakashansky K; Beddoe AM; Schadt E; Dottino P; Martignetti JA
    PLoS One; 2015; 10(12):e0145754. PubMed ID: 26717006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood.
    Higgins MJ; Jelovac D; Barnathan E; Blair B; Slater S; Powers P; Zorzi J; Jeter SC; Oliver GR; Fetting J; Emens L; Riley C; Stearns V; Diehl F; Angenendt P; Huang P; Cope L; Argani P; Murphy KM; Bachman KE; Greshock J; Wolff AC; Park BH
    Clin Cancer Res; 2012 Jun; 18(12):3462-9. PubMed ID: 22421194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel method for PIK3CA mutation analysis: locked nucleic acid--PCR sequencing.
    Ang D; O'Gara R; Schilling A; Beadling C; Warrick A; Troxell ML; Corless CL
    J Mol Diagn; 2013 May; 15(3):312-8. PubMed ID: 23541593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer.
    Kodahl AR; Ehmsen S; Pallisgaard N; Jylling AMB; Jensen JD; Laenkholm AV; Knoop AS; Ditzel HJ
    Mol Oncol; 2018 Jun; 12(6):925-935. PubMed ID: 29689598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy.
    Ma F; Zhu W; Guan Y; Yang L; Xia X; Chen S; Li Q; Guan X; Yi Z; Qian H; Yi X; Xu B
    Oncotarget; 2016 Oct; 7(40):66020-66031. PubMed ID: 27602761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations.
    Ogasawara A; Hihara T; Shintani D; Yabuno A; Ikeda Y; Tai K; Fujiwara K; Watanabe K; Hasegawa K
    Cancer Res Treat; 2020 Oct; 52(4):1219-1228. PubMed ID: 32599986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer.
    Markou A; Farkona S; Schiza C; Efstathiou T; Kounelis S; Malamos N; Georgoulias V; Lianidou E
    Clin Cancer Res; 2014 Nov; 20(22):5823-34. PubMed ID: 25398847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer.
    Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Inao T; Sueta A; Fujiwara S; Omoto Y; Iwase H
    Cancer Sci; 2015 Nov; 106(11):1582-9. PubMed ID: 26353837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of circulating plasma DNA in gastric cancer.
    Fang WL; Lan YT; Huang KH; Liu CA; Hung YP; Lin CH; Jhang FY; Chang SC; Chen MH; Chao Y; Lin WC; Lo SS; Fen-Yau Li A; Wu CW; Chiou SH; Shyr YM
    Int J Cancer; 2016 Jun; 138(12):2974-83. PubMed ID: 26815009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.